Clinical trials: Oral Phase
Healthy
A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants
The purpose of this study is to assess the absorption, metabolism, and excretion of JNJ-42756493 in healthy male adult participants after administration of a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed…
- Trial name
- NCT02692677
- Testing
- JNJ-42756493
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
- Trial name
- NCT00532675
- Testing
- LBH589, Lenalidomide
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Subjects
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
Compare the pharmacokinetics of Dihydroergotamine Mesylate (DHE) delivered by oral inhalation (MAP0004) or Intravenous (IV) DHE in smokers versus non-smokers.
- Trial name
- NCT01199965
- Testing
- MAP0004, IV DHE
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Allergan
Healthy
Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults
This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor. Verdinexor or placebo will be given on Days 1 and 3 to healthy adult participants.
- Trial name
- NCT02431364
- Testing
- Verdinexor
- Where
- Australia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Karyopharm Therapeutics Inc
High-grade Gliomas
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
The aim of the study was to explore the dose-limiting toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of TG02 capsules twice a week for 4 weeks.
- Trial name
- NCT03904628
- Testing
- TG02 capsules oral administration, BIW in every 28d
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Lee's Pharmaceutical Limited
Squamous Cell Carcinoma of the Head and Neck
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
This study involves another course of radiation (called re-irradiation) to the participant's tumor. The type of radiation is called stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02158234
- Testing
- Cisplatin, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
ADHD
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with…
- Trial name
- NCT06359899
- Testing
- AK0901 capsule
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
HIV Prevention, HIV Infections
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
To date, the majority of microbicide research has focused on the assessment of the safety and effectiveness of vaginal microbicides used for the prevention of HIV transmission via the vaginal compartment.
- Trial name
- RMP02-MTN006 (NCT00984971)
- Testing
- Tenofovir, Open label tenofovir tablet
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CONRAD
Haematological Malignancies
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate.
- Trial name
- NCT01080664
- Testing
- AS703569
- Where
- 10 sites in United States, Belgium and 3 more
- Volunteers
- 124 people
- Sponsor
- EMD Serono
Healthy Subjects
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
The primary objective is to evaluate the cardiac safety of a single oral dose (400 mg) of pacritinib compared to placebo on the QT calculated using the Fridericia correction (QTcF) interval in healthy subjects.
- Trial name
- NCT02807207
- Testing
- A: pacritinib, C: moxifloxacin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Carcinoma Breast Stage IV
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
1st-line treatment of HER2/neu overexpressing breast cancer
- Trial name
- NCT00433095
- Testing
- Navelbine, Herceptin, Navelbine (oraly)
- Where
- Germany
- Sponsor
- Ludwig-Maximilians - University of Munich
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01671007
- Where
- 522 sites in Austria, Belgium and 20 more
- Volunteers
- 10,471 people
- Sponsor
- Boehringer Ingelheim
Oral Mucositis
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers.
- Trial name
- PREVLAR (NCT03515538)
- Testing
- RRx-001, Cisplatin for injection, Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- EpicentRx, Inc.
Epilepsy Intractable
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy.
- Trial name
- NCT02987114
- Testing
- PLT101
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- PhytoTech Therapeutics, Ltd.
Diabetic Foot Infection
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects…
- Trial name
- NCT05369052
- Testing
- contezolid acefosamil (IV)/contezolid (PO), Linezolid (IV and PO)
- Where
- 14 sites in United States, Bulgaria and 6 more
- Volunteers
- 865 people
- Sponsor
- MicuRx
Ulcerative Colitis
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
This is a Phase IIa (proof of concept), randomized, double blind, placebo-controlled, multicentre clinical trial to evaluate the safety and efficacy of daily PBF-677 oral treatment during 28 days in Ulcerative colitis (UC)…
- Trial name
- ADENOIBD (NCT03773952)
- Testing
- PBF-677
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Palobiofarma SL
Solid Tumor, Adult
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
BY101921 is a novel small molecule, being developed as a PARP7 inhibitor which acts on the PARP7 catalytic subunit, for the treatment of solid tumors.
- Trial name
- NCT06433726
- Testing
- BY101921 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Parkinson's Disease
A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
The principal aim of this study is to obtain safety and tolerability data when PXT002331 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT02639221
- Testing
- PXT002331
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Prexton Therapeutics
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Healthy
A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers
The primary objective of the study is to determine the Pharmacokinetic (PK) and safety profiles of fampridine-PR 10 mg in Chinese and Japanese adult healthy volunteers.
- Trial name
- NCT01215084
- Testing
- BIIB041 (Fampridine-PR)
- Where
- 2 sites in Australia, Hong Kong
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.